Nomograms to Precisely Predict Conditional Risk of Recurrence for Patients With Laryngeal Cancer
NCT03595410 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2018-07-23
Summary
Advanced laryngeal squamous cell carcinoma (SCC) remains a highly morbid and fatal disease despite aggressive interventions. Mortality is high in this cohort: laryngeal cancer affects over 13 000 patients in the United States, with over 3500 deaths annually.The results of the Veterans Affairs Cooperative Studies Program Laryngeal Cancer Trial and subsequent studies demonstrated similar overall survival (OS) rates for organ preservation protocols involving radiotherapy (RT) or chemoradiotherapy (CRT) when compared to surgery, with the benefit of preserving the larynx in a large majority of patients. As such, the use of RT or CRT has become the predominant initial intervention for patients with laryngeal SCC.6 However, the prognosis of recurrent and persistent laryngeal SCC is particularly dire.In this study, we sought to identify preoperative predictors of survival for patients with recurrent or persistent laryngeal SCC in order to set patient expectations and address modifiable risk factors. Identification of predictors of survival may also identify patients who could benefit from novel therapeutic agents in a neo/adjuvant fashion. Herein,we examine a cohort of patients with recurrent or persistent laryngeal SCC after definitive RT/CRT who has undergone total laryngectomy in order to identify potential preoperative predictors of clinical outcomes.
Conditions
- Recurrent Laryngeal Cancer
Interventions
- OTHER
-
Recurrence laryngeal cancer
Recurrence laryngeal cancer has a wide range of invasion, rapid progression and poor prognosis.
Sponsors & Collaborators
-
First Affiliated Hospital, Sun Yat-Sen University
lead OTHER
Principal Investigators
-
Genglong Liu · First Affiliated Hospital, Sun Yat-Sen University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2020-01-01
- Completion
- 2020-01-01
Countries
- China
Study Locations
More Related Trials
-
Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
NCT01312350 ·Status: COMPLETED ·Phase: PHASE2
-
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
NCT06957938 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
NCT07065630 ·Status: RECRUITING ·Phase: PHASE2
-
Study of BKM120 in Advanced Squamous Cell Carcinoma of Head and Neck
NCT01527877 ·Status: UNKNOWN ·Phase: PHASE2
-
A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
NCT06894459 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
NCT04910347 ·Status: RECRUITING ·Phase: PHASE2
-
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00513435 ·Status: COMPLETED ·Phase: PHASE2
-
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx
NCT03388931 ·Status: WITHDRAWN ·Phase: PHASE4
-
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
NCT00939627 ·Status: COMPLETED ·Phase: PHASE2
-
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
NCT06442709 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study
NCT02281955 ·Status: COMPLETED ·Phase: PHASE2
-
A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
NCT04603248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
NCT01254617 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
NCT02538510 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
NCT05280457 ·Status: RECRUITING ·Phase: PHASE2
-
Head and Neck Cancer Treatment Related Dysphagia
NCT02657850 ·Status: WITHDRAWN
-
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT03707509 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Efficacy of Anlotinib in the Treatment of Recurrent Craniopharyngioma
NCT06970145 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
NCT03712397 ·Status: COMPLETED ·Phase: PHASE2
-
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00096512 ·Status: COMPLETED ·Phase: PHASE2
-
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
NCT04428151 ·Status: COMPLETED ·Phase: PHASE2
-
CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer
NCT01984502 ·Status: COMPLETED ·Phase: PHASE1
-
Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
NCT07088484 ·Status: NOT_YET_RECRUITING
-
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536 ·Status: COMPLETED ·Phase: PHASE2